

Title (en)

CHIMERIC AND HUMANISED ANTI-HUMAN IL-13 ANTIBODIES

Title (de)

CHIMÄRE UND HUMANISIERTE ANTI-HUMAN-IL-13-ANTIKÖRPER

Title (fr)

ANTICORPS CHIMERIQUES ET HUMANISES DIRIGES CONTRE L'IL-13 HUMAINE

Publication

EP 1976881 A2 20081008 (EN)

Application

EP 07703766 A 20070110

Priority

- EP 2007050219 W 20070110
- GB 0600488 A 20060111

Abstract (en)

[origin: WO2007080174A2] The present invention concerns immunoglobulins, particularly antibodies which specifically bind human Interleukin 13 (hIL-13). Antibodies of the invention may be used in the treatment of a variety of diseases or disorders responsive to modulation of the interaction between hIL-13 and the human IL-13 receptor. Such diseases include severe asthma, atopic dermatitis, COPD and various fibrotic diseases. Pharmaceutical compositions comprising said antibodies and methods of manufacture are also disclosed.

IPC 8 full level

C07K 16/24 (2006.01)

CPC (source: EP KR)

A61K 39/395 (2013.01 - KR); **A61P 1/00** (2017.12 - EP); **A61P 11/00** (2017.12 - EP); **A61P 11/02** (2017.12 - EP); **A61P 11/06** (2017.12 - EP); **A61P 25/00** (2017.12 - EP); **A61P 33/02** (2017.12 - EP); **A61P 33/12** (2017.12 - EP); **A61P 35/00** (2017.12 - EP); **A61P 35/02** (2017.12 - EP); **A61P 37/00** (2017.12 - EP); **A61P 37/08** (2017.12 - EP); **A61P 43/00** (2017.12 - EP); **C07K 16/24** (2013.01 - KR); **C07K 16/244** (2013.01 - EP); **C12N 5/10** (2013.01 - KR); **C12N 15/11** (2013.01 - KR); **A61K 2039/505** (2013.01 - EP); **C07K 2317/24** (2013.01 - EP); **C07K 2317/34** (2013.01 - EP); **C07K 2317/56** (2013.01 - EP); **C07K 2317/565** (2013.01 - EP); **C07K 2317/73** (2013.01 - EP); **C07K 2317/76** (2013.01 - EP); **C07K 2317/92** (2013.01 - EP); **Y02A 50/30** (2017.12 - EP)

Citation (search report)

See references of WO 2007080174A2

Citation (examination)

- WO 2004019975 A2 20040311 - GLAXO GROUP LTD [GB], et al
- WO 2004096849 A2 20041111 - UNIV MANITOBA [CA], et al
- WO 2006003407 A2 20060112 - GLAXO GROUP LTD [GB], et al
- WO 2005062967 A2 20050714 - TANOX INC [US], et al
- US 2006073148 A1 20060406 - TCHISTIAKOVA LIOUDMILA [US], et al
- HOLT L J ET AL: "Domain antibodies: proteins for therapy", TRENDS IN BIOTECHNOLOGY, ELSEVIER PUBLICATIONS, CAMBRIDGE, GB, vol. 21, no. 11, 1 November 2003 (2003-11-01), pages 484 - 490, XP004467495, ISSN: 0167-7799
- DAVIES J ET AL: "Affinity improvement of single antibody VH domains: residues in all three hypervariable regions affect antigen binding", IMMUNOTECHNOLOGY, ELSEVIER SCIENCE PUBLISHERS BV, NL, vol. 2, no. 3, 1 September 1996 (1996-09-01), pages 169 - 179, XP004070292, ISSN: 1380-2933

Designated contracting state (EPC)

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

Designated extension state (EPC)

HR

DOCDB simple family (publication)

WO 2007080174 A2 20070719; **WO 2007080174 A3 20071206**; AR 058955 A1 20080305; AU 2007204372 A1 20070719; BR PI0706481 A2 20110329; CA 2635972 A1 20070719; CN 101370829 A 20090218; CR 10161 A 20081126; EA 200801520 A1 20090227; EP 1976881 A2 20081008; GB 0600488 D0 20060222; IL 192207 A0 20081229; JP 2009523154 A 20090618; KR 20080113201 A 20081229; MA 30156 B1 20090102; NO 20082767 L 20081006; PE 20081185 A1 20081007; TW 200736274 A 20071001; ZA 200805526 B 20091028

DOCDB simple family (application)

EP 2007050219 W 20070110; AR P070100082 A 20070109; AU 2007204372 A 20070110; BR PI0706481 A 20070110; CA 2635972 A 20070110; CN 200780002297 A 20070110; CR 10161 A 20080717; EA 200801520 A 20070110; EP 07703766 A 20070110; GB 0600488 A 20060111; IL 19220708 A 20080616; JP 2008549873 A 20070110; KR 20087019555 A 20080808; MA 31108 A 20080711; NO 20082767 A 20080616; PE 2007000018 A 20070109; TW 96100833 A 20070109; ZA 200805526 A 20080624